Anthony Andolino

About Anthony Andolino

Anthony Andolino (age 56) is Vice President, Finance and Treasurer of Phibro Animal Health, serving as a corporate officer since March 2018 after joining Phibro in October 2011; he holds a B.B.A. in Public Accounting from Pace University and is a licensed CPA (New Jersey) . He has been entrusted as a designated company proxy holder alongside the General Counsel for the 2025 annual meeting, underscoring internal governance trust . Company performance context: in FY2025, Phibro delivered 27% net sales growth and a 65% increase in adjusted EBITDA, with cumulative TSR since FY2021 at 111 vs. 99 for the peer index, highlighting improving shareholder value creation .

Past Roles

External Roles

• No public company directorships or outside board roles disclosed for Mr. Andolino in the latest proxy filings .

Fixed Compensation

• Not disclosed. Mr. Andolino was not a named executive officer (NEO) in FY2025; the proxy provides detailed pay only for NEOs (CEO, CFO, COO, EVP Corporate Strategy, and SVP General Counsel) .

Performance Compensation

Company incentive design (applies to NEOs; broader executive participation not itemized by individual):

• Annual Management Incentive Plan (MIP) metrics and weights for FY2025: Sales (15%), Adjusted EBITDA (75%), Free Cash Flow metric tied to working capital (10%); payout range 50–150% of target based on performance . For FY2025, NEOs earned 137.3% of target under the MIP, with additional discretionary bonuses tied to the Zoetis MFA portfolio acquisition; targets/actuals for non-NEO executives (including Mr. Andolino) were not disclosed .

Notes:

• No FY2025 equity grants were made during the fiscal year; subsequent RSU grants on Aug 15, 2025 covered NEOs (CEO, CFO, COO, EVP Strategy, GC) and vest over three years with change-in-control protections, but Mr. Andolino was not included in the disclosed Aug 2025 RSU cohort .

Equity Ownership & Alignment

• Beneficial ownership: The proxy lists holdings for directors and NEOs; Mr. Andolino’s individual beneficial ownership is not enumerated in the table, indicating no reportable holdings above de minimis thresholds or that he was not included in the named group for disclosure .
• Hedging/derivatives: Senior Personnel are prohibited from transacting in company derivative securities and require pre-clearance for trades under the Insider Trading Policy; this framework reduces hedging/pledging risk, although the policy excerpt specifically references directors within “Senior Personnel” and does not single out Mr. Andolino by name .
• Clawback: A Dodd-Frank/Nasdaq-compliant clawback policy enables recovery of incentive-based compensation for current and former officers following a required financial restatement .

Employment Terms

• Employment agreements and severance: Disclosed contracts exist for the CEO, CFO, and COO (at-will, with defined severance and, for equity holders, specified vesting treatment), and a severance protection agreement for the General Counsel; the proxy explicitly notes no formal employment agreement for the EVP Corporate Strategy. No individual employment agreement or severance terms for Mr. Andolino were disclosed .

Performance & Track Record Context

Company-level performance during Andolino’s tenure in senior finance roles:

• FY2025 highlights: net sales $1,296.2m (+27% YoY), adjusted EBITDA $183.7m (+65% YoY), driven by Animal Health strength and the Zoetis MFA portfolio .
• Pay-versus-performance TSR: cumulative value of a $100 investment rose to 111 as of FY2025, versus 99 for the peer index used in the proxy .
• Say-on-Pay support: The most recent vote (2022) approved NEO compensation with ~99% support; the company continues triennial say-on-pay votes .

Company Financials (context)

*Values retrieved from S&P Global.

Investment Implications

• Incentive alignment and retention: Mr. Andolino is a long-tenured finance leader (corporate controller to VP Finance & Treasurer) with CPA credentials, indicating strong internal execution capability in reporting, controls, and treasury . However, there is no disclosure of individual equity grants or severance/change-in-control protections for him, unlike NEOs who received August 2025 RSUs with three-year vesting and change-in-control terms; this suggests less visible equity-based retention alignment for Andolino vs. NEOs, though he remains covered by company-wide insider trading and clawback policies .
• Performance backdrop: The surge in FY2025 sales and adjusted EBITDA, plus improving TSR vs. peers, reflects stronger operating momentum, a constructive setting for finance leadership to support capital allocation and balance sheet management .
• Trading signals and selling pressure: The proxy does not disclose Andolino’s beneficial ownership or any Form 4 activity; absent Form 4 data in the filings reviewed, there is no evidence of insider selling pressure attributable to Mr. Andolino. Additional review of recent Form 4s would be appropriate for a trading-signal assessment (not provided in the proxy set) .

Key gaps: Individual compensation metrics, equity ownership levels, vesting schedules, severance/change-of-control economics, and any pledging/hedging attestations for Mr. Andolino were not disclosed in the 2025 proxy. The company-level policies (insider trading, clawback) are in place and apply to officers, but Andolino-specific economics are not itemized .